Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Objective Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter, randomized, placebo‐controlled stu...

Full description

Saved in:

Bibliographic Details
Published in:	Arthritis & rheumatology (Hoboken, N.J.) Vol. 73; no. 10; pp. 1835 - 1846
Main Authors:	Isenberg, David, Furie, Richard, Jones, Nicholas S., Guibord, Pascal, Galanter, Joshua, Lee, Chin, McGregor, Anna, Toth, Balazs, Rae, Julie, Hwang, Olivia, Desai, Rupal, Lokku, Armend, Ramamoorthi, Nandhini, Hackney, Jason A., Miranda, Pedro, Souza, Viviane A., Jaller‐Raad, Juan J., Maura Fernandes, Anna, Garcia Salinas, Rodrigo, Chinn, Leslie W., Townsend, Michael J., Morimoto, Alyssa M., Tuckwell, Katie
Format:	Journal Article
Language:	English
Published:	Atlanta Wiley Subscription Services, Inc 01-10-2021
Subjects:	Adverse events Autoantibodies Bruton's tyrosine kinase c-Met protein Chronic conditions Complement component C4 Deoxyribonucleic acid DNA Double-blind studies Enzyme inhibitors Glucocorticoids Immunoglobulin G Immunoglobulin M Kinases Lupus Pharmacodynamics Pharmacology Placebos Response rates Safety Systemic lupus erythematosus Tyrosine Tyrosine kinase inhibitors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objective Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter, randomized, placebo‐controlled study. Methods Patients who had moderately to severely active SLE while receiving background standard therapy were randomized to receive placebo, fenebrutinib 150 mg once daily, or fenebrutinib 200 mg twice daily. Glucocorticoid taper was recommended from weeks 0 to 12 and from weeks 24 to 36. The primary end point was the SLE Responder Index 4 (SRI‐4) response at week 48. Results Patients (n = 260) were enrolled from 44 sites in 12 countries, with the majority from Latin America, the US, and Western Europe. The SRI‐4 response rates at week 48 were 51% for fenebrutinib 150 mg once daily (P = 0.37 versus placebo), 52% for fenebrutinib 200 mg twice daily (P = 0.34 versus placebo), and 44% for placebo. British Isles Lupus Assessment Group–based Combined Lupus Assessment response rates at week 48 were 53% for fenebrutinib 150 mg once daily (P = 0.086 versus placebo), 42% for fenebrutinib 200 mg twice daily (P = 0.879 versus placebo), and 41% for placebo. Safety results were similar across all arms, although serious adverse events were more frequent with fenebrutinib 200 mg twice daily. By week 48, patients treated with fenebrutinib had reduced levels of a BTK‐dependent plasmablast RNA signature, anti–double‐stranded DNA autoantibodies, total IgG, and IgM, as well as increased complement C4 levels, all relative to placebo. Conclusion While fenebrutinib had an acceptable safety profile, the primary end point, SRI‐4 response, was not met despite evidence of strong pathway inhibition.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23
ISSN:	2326-5191 2326-5205
DOI:	10.1002/art.41811